Home › Compare › ECDD vs MRK

ECDD vs MRK: Dividend Comparison 2026

ECDD yields 666666.67% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ECDD wins by $8.275235618773884e+34M in total portfolio value
10 years
ECDD
ECDD
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full ECDD calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — ECDD vs MRK

📍 ECDD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodECDDMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ECDD + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ECDD pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ECDD
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, ECDD beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ECDD + MRK for your $10,000?

ECDD: 50%MRK: 50%
100% MRK50/50100% ECDD
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ECDD
No analyst data
Altman Z
-701.1
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ECDD buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricECDDMRK
Forward yield666666.67% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$8.275235618773884e+34M$30.7K ✓
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00 ✓$950.29
Total dividends collected$8.275075881065991e+34M ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ECDD vs MRK ($10,000, DRIP)

YearECDD PortfolioECDD Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$66,677,367$66,666,666.67$11,192$351.54+$66.67M → ECDD
2$415,506,651,117$415,435,306,334.37$12,524$392.70+$415506.64M → ECDD
3$2,419,908,598,386,268$2,419,464,006,269,573.00$14,015$438.65+$2419908598.37M → ECDD
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$15,682$489.96+$13171697643084.44M → ECDD
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$17,547$547.23+$67004927492790120.00M → ECDD
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$19,632$611.16+$318562277003514871808.00M → ECDD
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$21,963$682.53+$1.415484168853553e+24M → ECDD
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$24,571$762.18+$5.878130573362507e+27M → ECDD
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$27,486$851.08+$2.2813793009840744e+31M → ECDD
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$30,745$950.29+$8.275235618773884e+34M → ECDD

ECDD vs MRK: Complete Analysis 2026

ECDD — Stock

Ecrid, Inc. offers products and services within the credit repair community. It provides an internet interactive software to allow consumers that need credit repair to track all the monthly payments they make and pay all their bills on-time. Ecrid, Inc. was incorporated in 2010 and is based in Stuart, Florida.

Full ECDD Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this ECDD vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ECDD vs SCHDECDD vs JEPIECDD vs OECDD vs KOECDD vs MAINECDD vs JNJECDD vs ABBVECDD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.